source
- Vor Bio pays RemeGen $10 million for rights to long-acting autoimmune drug candidate RC298Vor Bio announced a licensing agreement with RemeGen, paying $10 million upfront in cash and issuing warrants valued at about $46 million for rights to RC298 outside Greater China. RC298 is a long…
- STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatmentPfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.